利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.014 秒)

    PRO-DRUG PEPTIDE WITH IMPROVED PHARMACEUTICAL PROPERTIES
    3.
    发明申请
    PRO-DRUG PEPTIDE WITH IMPROVED PHARMACEUTICAL PROPERTIES 审中-公开

    公开(公告)号：US20190002519A1

    公开(公告)日：2019-01-03

    申请号：US16023901

    申请日：2018-06-29

    申请人： UREKA SARL

    发明人： Robert H. Zimmer ,  Gilles Guichard ,  Juliette Fremaux ,  Claire Venin ,  Sebastien Goudreau

    IPC分类号： C07K14/605 ,  A61K47/64 ,  A61P3/08

    摘要： The present disclosure relates to a pro-drug peptide, or a salt thereof, having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The pro-drug peptide comprising the following structure: Z-pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo releasing pep; n≥2 amino acids. The present disclosure also relates to methods of making and using the pro-drug peptide of the present disclosure. For example, the present disclosure describes a pro-drug peptide that may be used to prevent, treat, or ameliorate at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder.

    PRO-DRUG PEPTIDE WITH IMPROVED PHARMACEUTICAL PROPERTIES
    5.
    发明申请
    PRO-DRUG PEPTIDE WITH IMPROVED PHARMACEUTICAL PROPERTIES 有权

    公开(公告)号：US20210122800A1

    公开(公告)日：2021-04-29

    申请号：US17135627

    申请日：2020-12-28

    申请人： UREKA SARL

    发明人： Robert H. Zimmer ,  Gilles Guichard ,  Juliette Fremaux ,  Claire Venin ,  Sebastien Goudreau

    IPC分类号： C07K14/605 ,  A61K47/54 ,  A61K47/64 ,  A61P3/08

    摘要： The present disclosure relates to a pro-drug peptide, or a salt thereof, having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The pro-drug peptide comprising the following structure: Z-pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo releasing pep; n≥2 amino acids. The present disclosure also relates to methods of making and using the pro-drug peptide of the present disclosure. For example, the present disclosure describes a pro-drug peptide that may be used to prevent, treat, or ameliorate at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder.

    Pro-drug peptide with improved pharmaceutical properties
    6.
    发明授权
    Pro-drug peptide with improved pharmaceutical properties 有权

    公开(公告)号：US10889627B2

    公开(公告)日：2021-01-12

    申请号：US16023901

    申请日：2018-06-29

    申请人： UREKA SARL

    发明人： Robert H. Zimmer ,  Gilles Guichard ,  Juliette Fremaux ,  Claire Venin ,  Sebastien Goudreau

    IPC分类号： A61K38/00 ,  C07K14/605 ,  A61K47/54 ,  A61K47/64 ,  A61P3/08 ,  A61K38/26

    摘要： The present disclosure relates to a pro-drug peptide, or a salt thereof, having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The pro-drug peptide comprising the following structure: Z-pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo releasing pep; n≥2 amino acids. The present disclosure also relates to methods of making and using the pro-drug peptide of the present disclosure. For example, the present disclosure describes a pro-drug peptide that may be used to prevent, treat, or ameliorate at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder.